 SAN DIEGO, April 08, 2022 GLOBE NEWSWIRE -- BioAtla, Inc. Nasdaq: BCAB, a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic CAB antibody and other protein therapeutics, today announced that it plans to host a conference call and webcast on Wednesday, May 4, 2022 at 4:30 p.m. Eastern Time to discuss its financial results for the quarter ended March 31, 2022, and provide an interim topline data update from the mecbotamab vedotin BA3011 Phase 2 study in sarcoma as well as an operational update on our ongoing clinical programs, including BA3011, ozuriftamab vedotin BA3021 and CAB-CTLA-4 BA3071. 